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Abstract
Aim: Pancreatic neuroendocrine tumors (pNETs) can occur
in patients with a familial syndrome either as multiple endocrine neoplasia type 1 (MEN-1) or as sporadic tumors. Endoscopic ultrasound (EUS) has become one of the first-line investigations for pNET characterization. The ultrasonographic features of pNETs may differ depending on the familial
versus sporadic pathogenesis of the tumor. Therefore, the
EUS findings could help and direct the definition of a pNET
with an impact on the most appropriate diagnostic and therapeutic patient management. Methods: In this single-center
retrospective study, we reviewed the EUS features of 94
pNETs from 37 MEN-1 patients and 15 pNETs from 11 spo-
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radic disease patients at the time of their first EUS assessment. We analyzed the most relevant morphological and ultrasonographic characteristics of the tumors and compared
the findings between the 2 patient groups. Results: Patients
with MEN-1 more likely present with multiple pNETs than
patients with sporadic disease. Sporadic pNETs are usually
much bigger than those due to MEN-1. Moreover, pNETs are
more heterogeneous in patients with sporadic disease than
in those with MEN-1. No statistical difference with regard to
definition of the margins, morphology, and vascularization
of the pNETs appears between the 2 groups. Conclusions:
Patients with sporadic disease usually present with bigger
and more heterogeneous pNETs than patients with MEN-1,
who tend to present with a higher number of lesions. EUS
can facilitate the precise characterization of a pNET, and the
ultrasonographic features of the lesion can help and distinguish MEN-1-related versus sporadic disease.
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Neuroendocrine tumors represent a heterogeneous
group of neoplasms from a biological, anatomical, and
clinical point of view. Approximately, 5% of all neuroendocrine tumors originate from the pancreas and the estimated incidence of pancreatic neuroendocrine tumors
(pNETs) is 0.32/100,000/year [1]. From a pathogenetic
perspective, pNETs can occur in patients with a familial
syndrome or they can be sporadic as well [2]. Among the
familial syndromes potentially leading to the development of a pNET, multiple endocrine neoplasia type 1
(MEN-1) is the definitely most frequent condition, followed by von Hippel-Lindau disease, neurofibromatosis
1 (von Recklinghausen disease), and the tuberous sclerosis complex [3]. The genetic background of the pNET determines some differences in the diagnostic and therapeutic approach and dictate specifically targeted followup plans. In such a setting, all investigations and
techniques that can help with the determination of the
familial rather than sporadic nature of the pNET are valuable.
In MEN-1 patients, pNETs occur in 30–80% of the cases and may either secrete or not secrete hormones [4].
Moreover, the age of pNET onset is earlier in MEN-1 patients than in the patients with sporadic disease [5].
Though recommendations and guidelines have been
published, the optimal managements of pNETs in MEN1 still remain controversial, especially with regard to the
nonfunctioning tumors [4, 6, 7].
In the last decade, endoscopic ultrasound (EUS) has
become one of the first-line imaging investigations for the
characterization of pNETs [8, 9] and has a clearly defined
role in the multidisciplinary diagnostic approach to pNET
[10]. In experienced hands, EUS has sensitivity for pNETs
ranging between 80 and 90% and specificity above 95%
[11, 12]. In MEN-1 patients, EUS appears to be the most
sensitive method for the detection of pNETs even when
they are pretty small in size [4, 13–15]. The diagnostic
value of EUS can go beyond this aspect, as such a technique may help with the retrieval of histological or cytological specimens for pathology examination. Moreover,
the EUS features of a pNET might differ depending on the
familial versus sporadic nature of the tumor and can direct the subsequent steps of tumor diagnosis and localization. Therefore, the EUS findings by themselves might
help and direct the accuracy of the definition of a pNET
at the time of its first detection, with a possible impact on
the most appropriate diagnostic and therapeutic management of the patient found to carry the lesion.
EUS in MEN-1 and Sporadic pNETs

In our study, we have collected, analyzed, and compared the EUS features of pNETs occurring in a singlecenter series of patients with MEN-1 versus those of
pNETs occurring sporadically.
Methods
In this single-center retrospective study, we have collected, reviewed, and analyzed the EUS characteristics of 94 pNETs from 37
patients with MEN-1 and 15 pNETs from 11 patients with sporadic disease at the time of their first EUS assessment (Table 1).
The patients consecutively attended our institution over a 5-year
time period (from September 2002 to July 2007).
EUS was carried out by 2 investigators using a Pentax FG-32UA
and FG-36UX endosonoscope (Pentax Corporation, Tokyo,
Japan) with a longitudinal 7.5 MHz sector array in combination
with a Hitachi EUB-420 or Hitachi EUB-525 computational system (Hitachi Medical Corporation, Tokyo, Japan) [16]. The vascularization of the tumors was assessed with duplex ultrasonography after a careful optimization of the Doppler technique and an
appropriate gain setting for avoiding the appearance of noise.
Patients underwent EUS with conscious sedation. All EUS
procedures were carried out as per the appropriate diagnostic
management of the patients and were uneventful with regard to
the occurrence of adverse events. With the goal of defining the
EUS features of MEN-1-related versus sporadic pNETs, we have
reviewed the most relevant morphological and ultrasonographic
aspects of the tumors as described in the EUS reports and compared the findings between the 2 patient groups. First of all, the
number and the size of the tumors have been recorded. Then, the
definition of the margin (well defined versus not well defined), the
morphology (round/oval versus speckled), the appearance (homogeneous versus heterogeneous), and the vascularization (hypervascular versus non-hypervascular) of the tumors have been
evaluated.
The relevant data have been subsequently anonymized and
stored in a password-protected system. The statistical evaluation
of the data has been carried out using the analysis of variance when
assessing the pNET maximum diameter, taking a p value <0.05
as the cutoff for statistical significance. The EUS characteristics of
the pNETs, including the number of lesions detected in each patient, have been analyzed using the Barnard’s test, taking again a p
value <0.05 as the cutoff for significance. Barnard’s test is an exact
unconditional nonparametric test for the analysis of contingency
tables, which uses a more computationally intensive algorithm for
creating a rejection region [17], finally representing a more powerful alternative to Fisher’s exact test.
This retrospective study has been carried out in accordance
with the principles of the Declaration of Helsinki.

Results

Our study shows that, at the time of the first EUS detection of a pNET, patients with MEN-1 appear more
likely to present with multiple lesions in comparison to
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Introduction

Patient

Number of tumors

Maximum diameter, mm

Clinicopathological characterization

Patients with MEN-1
1
32
2
50
3
77
4
35
5
38
6
47
7
19
8
45
9
25
10
52
11
18
12
39
13
34
14
35
15
50
16
51
17
58
18
65
19
33
20
29
21
50
22
46
23
28
24
48
25
38
26
47
27
38
28
52
29
23
30
72
31
57
32
47
33
51
34
26
35
41
36
35
37
56

6
4
1
2
4
2
4
2
2
2
1
2
1
1
2
6
2
5
2
5
2
1
2
6
1
2
1
2
3
4
1
2
5
1
3
1
1

21
14
10
10
5
7
14
12
6
6
4
6
5
4
12
12
26
12
11
26
13
5
4
12
5
10
13
25
8
14
18
3
8
4
5
8
6

Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Insulinoma, nonfunctioning
Insulinoma
Nonfunctioning
Insulinoma
Nonfunctioning
Gastrinoma
Nonfunctioning
Insulinoma, nonfunctioning
Nonfunctioning
Nonfunctioning
Insulinoma, nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Gastrinoma
Gastrinoma, nonfunctioning
Nonfunctioning
Gastrinoma
Nonfunctioning
Nonfunctioning
Insulinoma
Nonfunctioning
Gastrinoma, insulinoma
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning

Patients with sporadic disease
1
63
2
68
3
63
4
59
5
26
6
29
7
69
8
66
9
77
10
38
11
68

1
1
2
3
1
2
1
1
1
1
1

8
60
6
24
65
45
7
14
25
9
26

Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
Insulinoma
Glucagonoma
Nonfunctioning
Nonfunctioning
Nonfunctioning
Nonfunctioning
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Table 1. Clinicopathological features of 48 patients with one or more pNETs occurring in the setting of MEN-1 or as sporadic disease

The diagnosis of pNETs is affected by a number of
relevant challenges, which include the pathogenetic nature, the localization, the definition of the number of
the tumors, and first of all their identification. These
issues probably arise in a more striking way when the
EUS in MEN-1 and Sporadic pNETs

50

40

30

20

10

MEN

Sporadic

Fig. 1. Comparison of the size of pNETs detected by EUS in pa-

tients with MEN-1 (MEN) and in patients with sporadic disease
(Sporadic). p value <0.001.

Table 2. Analysis of the most relevant EUS features of pNETs in

patients with MEN-1 (MEN) and in patients with sporadic disease
(Sporadic).
MEN

Sporadic Barnard’s test,
p value

Well defined
Not well defined

75
19

8
7

0.058

Round/oval
Speckled

92
2

14
1

0.383

Homogeneous
Heterogeneous

74
20

3
12

<0.001

Non-hypervascular
Hypervascular

4
90

0
15

0.525

pNET does not secrete any hormone leading to a specific endocrine syndrome. In such a challenging setting,
many biochemical markers or radiological techniques
can be of value and should be used with the goal of
clarifying in the most precise way the disease, as this
point has an extremely important role for the establishment of the best plan of surgical and/or medical treatment and follow-up [4, 8, 9]. Moreover, in the case of
Digestion 2018;98:112–118
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Discussion

60

Size of lesion, mm

patients with the sporadic disease (2.5 vs. 1.4 tumors/
patient). Despite a pretty well-defined trend, such finding did not reach statistical significance (p = 0.163). On
the contrary, pNETs occurring in patients with sporadic
disease tend to be significantly bigger than those arising
in the setting of MEN-1 (p > 0.001) and, more in the specific, the sporadic pNETs are 3 times bigger than the
MEN-1-related lesions (23 vs. 7 mm; Fig. 1). With regard to the tumor size, patients with sporadic disease
also display a much greater variability than patients with
MEN-1, presenting with lesions, which range from 4 to
65 mm versus 3 to 26 mm. In sporadic disease patients,
about half of the lesions had a maximum diameter between 10 and 30 mm and about a quarter of the lesions
had a much bigger size, with maximum diameter above
40 mm. In patients with MEN-1, two thirds of the pNETs
had a diameter smaller than 10 mm, with a non-negligible portion of them being just at the size limit for detection. Only very few lesions had a maximum diameter
above 20 mm and none of them was close to 30 mm in
size.
In patients with sporadic disease, the tumors appear
to be significantly more heterogeneous than in patients
with MEN-1 (Table 2). The large majority of MEN-1-related pNETs have a homogeneous appearance. An illustrative EUS picture of homogenous versus heterogeneous pNET is provided (Fig. 2a, b). On the contrary, in
terms of the features concerning their EUS appearance,
there is no statistical difference with regard to the definition of the margins, the morphology, and the vascularization of the pNETs between the 2 groups. However, the
observation that 3 quarters of pNETs arising in MEN-1
patients have well-defined margins is remarkable, also
considering the fact that the rate between lesions with
well-defined versus not well-defined margins in sporadic disease patients is much more equilibrated. However,
such observation did not achieve any statistical significance in our patient population. Finally, it may be worth
noticing that almost all pNETs have a round/oval shape
and appear to be hypervascular regardless of their pathogenesis.

a

b

Fig. 2. An illustrative EUS picture of a homogeneous pNET (a) of a patient with MEN-1 and a heterogeneous
pNET of a patient with sporadic disease (b).
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vation if we consider the pathogenesis of MEN-1-related
versus sporadic lesions. This finding lacks statistical significance and can be affected by the size of the study population, which might not be large enough for confirming
such observation also from a statistical point of view, and
by the fact that our EUS study takes into consideration
only the first investigation performed for each patient,
thus ignoring the very likely subsequent detection of additional lesions overtime with the successive EUS assessments. However, once a pNET is disclosed at EUS for the
first time in a MEN-1 patient, it appears to be probable
that another or even more other pancreatic lesions are
already detectable. On the other hand, sporadic pNETs
are roughly 3 times bigger than those detected in MEN-1
patients and such a finding achieved a very strong statistical significance in our study population. While MEN1-related pNETs have usually a sub-centimeter diameter,
sporadic pNETs often present with a diameter close to or
bigger than 2 cm.
With regard to the ultrasonographic features of the
pNETs, only the heterogeneous versus the homogeneous appearance of the tumor seems to have a statistical relevance in the distinction between sporadic and
MEN-1-related tumors. While sporadic pNETs are often heterogeneous, the lesions observed in MEN-1 patients are often homogeneous. To the best of our knowledge, a definite explanation for such EUS difference between the 2 patient groups is not available, though
maybe the presence of areas of necrosis arising in the
largest tumors might account for some intra-lesion ultrasonographic heterogeneity [24]. Interestingly and
possibly somehow linked to this last observation, the
majority of pNETs arising in MEN-1 patients have
Tamagno/Scherer/Caimo/Bergmann/
Kann
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pNETs occurring in patients with a familial syndrome,
like MEN-1, an early diagnosis is not only necessary for
treating the patients on time but also extremely useful
for defining the times of the successive follow-up assessments and the screening of the family members
[18–20].
With the optimization of the materials and techniques,
EUS is progressively assuming the prominent position as
first choice imaging procedure for the assessment of the
pancreas in MEN-1 patients, being superior to CT, MRI,
and somatostatin receptor scintigraphy [21, 22]. In such
patient population, somatostatin receptor scintigraphy is
considered being the most reliable method for the detection of metastatic disease [4]. A possible limitation of EUS
sensitivity for the detection of pNETs may be represented
by the localization of the tumor, as the lesions localized in
the tail of the pancreas might remain hidden, especially if
they are small in size. The high sensitivity and high specificity of EUS for the detection of pNETs and its value for
the ultrasonographic characterization of the tumor obviously depend very much on the experience and ability of
the investigator. Furthermore, its cost effectiveness is an
additional factor supporting the increasing use of this investigation [23]. Even though the availability of EUS has
dramatically spread in the last decade and the technique
is now very largely used in the third-level and many second-level hospitals, the unfortunate possibility of this investigation being not performed in the work-up of a suspicious pNET still exists and may depend on many factors.
In our study population, pNETs tend to be more numerous (almost twice) in patients with MEN-1 than in
those with sporadic disease, which is a predictable obser-

well-defined margins, while sporadic pNETs can equally present either with well-defined or not well-defined
margins. However, the mild difference affecting the
characteristics of the margins of the pNETs of the 2 patient groups did not achieve any statistical significance
in our patient population, and maybe a comparison in
other, or larger, patient populations might lead to a better definition of the clinical relevance of such EUS feature. Regardless of their pathogenesis, almost all pNETs
have a round/oval shape and are hypervascular, highlighting a specific pattern that virtually characterizes
the neuroendocrine neoplasms originating from Langerhans islet. We are of the opinion that a larger and
multicenter patient population could elucidate further
the EUS features of pNETs and we believe that a confirmation of our original data could increase the clinical
relevance of this set of observations. Over and above the
pNETs ultrasonographic characteristics observed
through EUS, such a sensitive and specific investigation
also represents a reliable and effective support for performing a lesion biopsy, with an obvious subsequent

clinically relevant impact in terms of diagnostic characterization, pathogenetic definition, and prognosis of the
pNET [25–27]. Moreover, EUS can also be associated
to radiofrequency ablation of pancreatic tumors, including those of neuroendocrine origin [28].
In conclusion, EUS can help with the precise characterization of pNETs, including the definition of ultrasonographic features, which can distinguish MEN-1-related versus sporadic disease. At the time of the first EUS
assessment of a patient with a pNET, the presence of a
single big heterogeneous lesion suggests facing most likely a sporadic disease while the detection of 1 or more subcentimeter lesions with homogeneous aspect and welldefined margins is more likely to characterize a pNET
related to MEN-1.
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